Table 1.
The summary of ITGB3 inhibitors
| Inhibitor | Mechanism | Clinical trials | Reference |
|---|---|---|---|
| Cilengitide | Selectively bind to the ligand of integrin αvβ3 | NCT01118676 Phase I NSCLC | PMID: 21269250 |
| NCT00121238 Phase II Prostate cancer | [100] | ||
| NCT01044225 Phase II | PMID: 21049281 | ||
| GBM | [89] | ||
| NCT00689221 Phase III | PMID: 25163906 | ||
| GBM | [91] | ||
| MK-0429 | Selectively inhibit binding of the ligand to integrin β3 | NCT00302471 Phase I | PMID: 20398037 |
| Hormone Refractory Prostate Cancer and Metastatic Bone Disease | [94] | ||
| Vitaxin | Integrin ανβ3-specific monoclonal antibody | NCT00066196 Phase II Metastatic melanoma | PMID: 9600913 |
| NCT00072930 Phase II Metastatic Androgen-Independent Prostate Cancer | [103] | ||
| Luteolin | Inhibit the integrin β3-FAK signal pathway | Null | PMID: 22983392 |
| [104] | |||
| Methylseleninic acid (MSA) | Down-regulate integrin β3 signal pathway | Null | PMID: 28842587 |
| [105] | |||
| Phoyunnanin E | Down-regulate integrins αv and β3 | Null | PMID: 29284478 |
| [106] | |||
| Pinocembrin | Inactivate the integrin β3-FAK-p38α signaling pathway | Null | PMID: 25949790 |
| [107] |